Literature DB >> 3265825

Serum lactic dehydrogenase predicts mortality in patients with AIDS and Pneumocystis pneumonia.

M L Lipman, E Goldstein.   

Abstract

Serum lactic dehydrogenase (LDH) activity was compared with mortality in patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia during the first four days of admission to assess the test's predictive value. In 30 admissions, 29 patients who survived an episode of Pneumocystis pneumonia had a mean LDH value of 385 IU, with five values greater than 520 IU. Eight with pneumonia who died had a mean value of 926 IU: all had values higher than 520 IU. The mean LDH values for 20 patients with AIDS (35 admissions) who survived and 4 who died of non-Pneumocystis disease were 240 IU and 350 IU, respectively; these patients were the control population. The positive and negative predictive values for survival using 520 IU as the threshold are 61% and 100%. Thus, LDH measurements in the first days of admission for P carinii pneumonia predict mortality and are useful in guiding future management.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265825      PMCID: PMC1026521     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  9 in total

1.  Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  C P Kales; J R Murren; R A Torres; J A Crocco
Journal:  Arch Intern Med       Date:  1987-08

2.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

3.  Corticosteroids as adjunctive therapy in treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  D K MacFadden; J D Edelson; R H Hyland; C H Rodriguez; T Inouye; A S Rebuck
Journal:  Lancet       Date:  1987-06-27       Impact factor: 79.321

4.  Prognostic factors in Burkitt's lymphoma: importance of total tumor burden.

Authors:  I Magrath; Y J Lee; T Anderson; W Henle; J Ziegler; R Simon; P Schein
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

5.  Serum lactate dehydrogenase levels in adults and children with acquired immune deficiency syndrome (AIDS) and AIDS-related complex: possible indicator of B cell lymphoproliferation and disease activity. Effect of intravenous gammaglobulin on enzyme levels.

Authors:  B A Silverman; A Rubinstein
Journal:  Am J Med       Date:  1985-05       Impact factor: 4.965

6.  Evidence for destruction of lung tissues during Pneumocystis carinii infection.

Authors:  R H Eng; E Bishburg; S M Smith
Journal:  Arch Intern Med       Date:  1987-04

7.  Radiographic resolution of Pneumocystis carinii pneumonia in response to corticosteroid therapy.

Authors:  J A Rankin; J A Pella
Journal:  Am Rev Respir Dis       Date:  1987-07

8.  Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome.

Authors:  L A Engelberg; C W Lerner; M L Tapper
Journal:  Am Rev Respir Dis       Date:  1984-10

9.  Prognostic significance of serum lactate dehydrogenase in malignant lymphoma.

Authors:  R J Schneider; K Seibert; S Passe; C Little; T Gee; B J Lee; V Miké; C W Young
Journal:  Cancer       Date:  1980-07-01       Impact factor: 6.860

  9 in total
  2 in total

1.  Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy.

Authors:  R F Miller; E Allen; A Copas; M Singer; S G Edwards
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

2.  Outcomes of HIV-associated pneumocystis pneumonia at a South African referral hospital.

Authors:  Nondumiso Chiliza; Mariette Du Toit; Sean Wasserman
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.